Development of a delivery system for the continuous endogenous release of an anti-idiotypic antibody against ovarian carcinoma

Hybridoma

Volumn 24, Issue 3, 2005, Pages 133-140

  Hann, Evelin ^a   Reinartz, Silke ^a   Clare, Susan E ^b   Passow, Sebastian ^a   Kissel, Thomas ^a   Wagner, Uwe ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; CHIMERIC ANTIBODY; IMMUNOGLOBULIN FC FRAGMENT; MONOCLONAL ANTIBODY; POLYETHERSULFONE; POLYETHYLENE TEREPHTHALATE; POLYVINYLIDENE FLUORIDE; TUMOR ANTIGEN;

ANIMAL CELL; ANTIBODY PRODUCTION; ARTICLE; CELL ENCAPSULATION; CELL SURVIVAL; CELL VIABILITY; DRUG DELIVERY SYSTEM; GENETIC TRANSFECTION; HOLLOW FIBER; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; MOLECULAR WEIGHT; MYOBLAST; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL;

ANIMALIA; MURINAE;

EID: 20844434052     PISSN: 15540014     EISSN: None     Source Type: Journal    
DOI: 10.1089/hyb.2005.24.133     Document Type: Article

References (23)

1. Reinartz S, Köhler S, Schlebusch H, Krista K, Giffels P, Renke K, Huober J, Möbus V, Kreienberg R, Sabbatini P, and Wagner U: Vaccination of patients with advanced ovarian carcinoma with the anti-idiotypic antibody ACA125: immunological response and survival (phase Ib/II study). Clin Cancer Res 2004;10:1580-1587.
2. Bhattacharya-Chatterjee M, Chatterjee SK, and Foon KA: Anti-idiotype vaccines against cancer. Immunol Lett 2000;74:51-58.
3. Foon KA, Lutzky J, Baral RN, Yanelli JR, Hutchins L, Tietelbaum A, Kashala OL, Das R, Garisson J, Reisfeld RA, and Bhattacharya-Chatarjee M: Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2. J Clin Oncol 2000;18:376-384.
4. Durrant GL, Buckley DJ, Robins RA, and Spendlove I: 105AD7 cancer vaccine stimulates anti-tumour helper and cytotoxic T-cell responses in colorectal cancer but repeated immunisations are required to maintain these responses. Int J Cancer 2000;85:87-92.
5. + (MUC-16) ovarian cancer. Cancer Res 2003;63:3234-3240.
6. Wagner U, Köhler S, Reinartz S, Giffels P, Huober J, Renke K, Schlebusch H, Biersack HJ, Möbus V, Kreienberg R, Bauknecht T, Krebs D, and Wallwiener D: Immunological consolidation of ovarian carcinoma recurrences with monoclonal anti-idiotype antibody ACA125: immune responses and survival in palliative treatment. Clin Cancer Res 2001;7:1154-1162.
7. Critchfield JM, Zuniga-Plucker JC, and Leonardo MJ: Parameters controlling the programmed death of mouse T lymphocytes in high-dose suppression. Cell Immunol 1995;160:71-78.
8. Cirone P, Saller RM, and Chang P: Immuno-isolation in oncology-a mini-review. Curr Pharm Biotechnol 2001;2:269-277.
9. Uludag H, De Vos P, and Tresco PA: Technology of mammalian cell encapsulation. Adv Drug Deliv Rev 2000;42:29-64.
10. Li RH: Materials for immunoisolated cell transplantation. Adv Drug Deliv Rev 1998;33:87-109.
11. Deglon N, Heyd B, Tan SA, Joseph JM, Zurn AD, and Aebischer P: Central nervous system delivery of recombinant ciliary neutrophic factor by polymer encapsulated differentiated C2C12 myoblasts. Hum Gene Ther 1996;7:2135-2146.
12. Read TA, Sorensen DR, Mahesparan R, Enger P, Timpl R, Olsen BR, Hjelstuen MHB, Haraldseth O, and Bjerkvig R: Local endostatin treatment of gliomas administered by microencapsulated producer cells. Nat Biotechnol 2001;19:29-34.
13. Joki T, Machluf M, Atala A, Zhu J, Seyfried NT, Dunn IF, Abe T, Carroll RS, and Black PML: Continuous release of endostatin from microencapsulated engineered cells for tumor therapy. Nat Biotechnol 2001;19:35-39.
14. Bachoud-Levi AC, Deglon N, Nguyen JP, Bloch J, Bourdet C, Winkel L, Remy P, Goddard M, Lefaucheur JP, Brugieres P, Baudic S, Cesaro P, Peschanski M, and Aebischer P: Clinical protocol. Neuroprotective gene therapy for Huntington's disease using a polymer encapsulated BHK cell line engineered to secrete human CNTF. Hum Gene Ther 2000;11:1723-1729.
15. Aebischer P, Schluep M, Deglon N, Joseph J, Hirt L, Heyd B, Goddard M, Hammang JP, Zurn A, Kato AD, Regli F, and Baetge EE: Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nat Med 1996;2:696.
16. Brauker J, Martinson LA, Young SK, and Johnson RC: Local inflammatory response around diffusion chambers containing xenografts: nonspecific destruction of tissues and decreased local vascularization. Transplantation 1996;61:1671-1677.
17. + T cells and B cells. Transplantation 1996; 61:1678-1684.
18. Peduto G, Rinsch C, Schneider BL, Rolland E, and Aebischer P: Long-term host unresponsiveness to encapsulated xenogeneic myoblasts after transient immunosupression. Transplantation 2000;70: 78-85.
19. Cannon MJ, Santin AD, and O'Brien TJ: Immunological treatment of ovarian cancer. Curr Opin Obstet Gynecol 2004;16:87-92.
20. Yin BWT, Dnistrian A, and Lloyd KO: Ovarian cancer antigen CA125 is encoded by the MUC16 mucin gene. Int J Cancer 2002;98:737-740.
21. Whitehouse C, and Solomon E: Current status of the molecular characterization of the ovarian cancer antigen CA125 and the implications for its use in clinical screening. Gynecol Oncol 2003; 88:152-157.
22. Li RH, Williams S, Burkstrand M, and Roos E: Encapsulation matrices for neutrophic factor-secreting myoblast cells. Tissue Eng 2001;6:151-163.
23. Dionne KE, Cain BM, Li RH, Bell WJ, Doherty EJ, Rein DH, Lysaght MJ, and Gentile FT: Transport characterization of membranes for immunoisolation. Biomaterials 1996;17:257-266.